SCHEMBL18735343

SCHEMBL18735343

CCOC(=O)CC(=O)C(=O)SC(C)C(NC(=O)CC)C(=O)OCC

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ MGAM O43451 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ SI P14410 1/20 0.38
▸ MGAM2 Q2M2H8 1/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ POLB P06746 1/20 0.38
▸ CYP1A2 P05177 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ LMNA P02545 1/20 0.32
▸ METAP2 P50579 4/20 0.32
▸ METAP1 P53582 3/20 0.32
▸ CAD P27708 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18735371 0.93 L3MBTL1 (0.35) L3MBTL1MGAMGAASIMGAM2
SCHEMBL18735373 0.91 L3MBTL1 (0.34) L3MBTL1KMT2APOLB
SCHEMBL18735377 0.86 MGAM (0.38) L3MBTL1MGAMGAASIMGAM2
SCHEMBL18734952 0.86 MGAM (0.33) L3MBTL1MGAMGAASIMGAM2
SCHEMBL18735073 0.86 GAA (0.40) L3MBTL1MGAMGAASIMGAM2
SCHEMBL18735331 0.80 METAP2 (0.33) L3MBTL1KMT2APOLBCYP1A2CYP2C9
SCHEMBL18735077 0.79 KMT2A (0.35) L3MBTL1MGAMGAASIMGAM2
SCHEMBL18735332 0.78 KMT2A (0.32) L3MBTL1KMT2APOLBCYP2C9CYP2C19
SCHEMBL18735378 0.77 METAP2 (0.32) L3MBTL1KMT2APOLBMETAP2METAP1
SCHEMBL18735375 0.77 METAP2 (0.32) L3MBTL1KMT2APOLBMETAP2METAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017060400-A1 PROTECTED CARBOXYLIC ACID-BASED METABOLITES FOR THE TREATMENT OF DISESASES RELATED TO MITOCHONDRIAL DYSFUNCTIONS NEUROVIVE PHARMACEUTICAL AB (SE) 2017-04-13 — — WO disclosed
Send feedback